keynote-890: tavo in combination with keytruda for late-stage triple negative breast cancer patients
Published 5 years ago • 590 plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
4:50
triple negative breast cancer update: immunotherapy in stage 2-3 tnbc (keynote 522 update)
-
1:29
immunotherapy keytruda shows benefit in early triple-negative breast cancer
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
0:53
enhancing triple negative breast cancer treatment with immunotherapy across all settings
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
6:16
latest on immunotherapy in triple-negative breast cancer - medpage today
-
5:01
keynote-522: final os findings of pembrolizumab and chemotherapy in tnbc
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
3:37
tnbc: immunotherapy in the neoadjuvant setting
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
1:30
begonia: durvalumab combinations in advanced tnbc
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
4:11
keytruda immunotherapy for triple negative breast cancer
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...